Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

Published:2021-03-18 Issue:11 Volume:127 Page:1816-1826
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Martin Thomas G.¹^ORCID,Shah Nina¹^ORCID,Richter Joshua²,Vesole David H.³,Wong Sandy W.¹,Huang Chiung‐Yu⁴,Madduri Deepu²,Jagannath Sundar⁵^ORCID,Siegel David S.³,Biran Noa³,Wolf Jeffrey L.¹,Parekh Samir²,Cho Hearn J.⁵,Munster Pamela¹,Richard Shambavi²,Ziti‐Ljajic Samira⁶,Chari Ajai²^ORCID

Affiliation:

1. Hematology/Oncology University of California San Francisco Medical Center San Francisco California

2. Hematology and Oncology Icahn School of Medicine at Mount Sinai New York New York

3. Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey

4. Department of Epidemiology and Biostatistics University of California San Francisco San Francisco California

5. Tisch Cancer InstituteIcahn School of Medicine at Mount Sinai New York New York

6. Translational Medicine and Early Development, Pharmacokinetic and Drug Metabolism, Pharmacokinetic Unit, Sanofi Paris France

Funder

Sanofi

Amgen

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33448

Reference28 articles.

1. Treatment of relapsed multiple myeloma: Evidence-based recommendations

2. Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021

3. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

4. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

5. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report;Oncohematology;2023-12-08

2. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02

3. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

4. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes;Annals of Hematology;2022-08-09

5. Anti CD38 monoclonal antibodies for multiple myeloma treatment;Human Vaccines & Immunotherapeutics;2022-04-11